Broad Spectrum Distillate
$1,250.00
-11%
CBD Isolate
$400.00
-15%
CBG Isolate
$1,800.00
-1%
Water Soluble CBD
$2,500.00
-8%
Back to news
28. April 2020
Food & Beverage News Regulation United Kingdom

UK’s FSA Confirms 31 March 2021 Deadline for CBD Companies

The UK’s Food Standards Agency (FSA) has confirmed that they intend to stick to their deadline of the 31st of March 2021 for CBD companies to have a validated Novel Foods application.

In a virtual meeting with the Association for the Cannabinoid Industry (The ACI), the FSA quashed any speculation that they would extend the deadline for all UK businesses, as a result of the COVID-19 outbreak.

In a statement published on the ACI website, the organisation confirmed that they had been in discussions with the FSA in order to clarify several points that have now been shared with ACI members and the wider industry:

The statement confirms that the FSA made it clear that:

  • They will not consider extending the deadline of 31 March 2021 for CBD companies to have a validated Novel Foods application in order to remain on the UK market.
  • They made it clear that they would not consider changing the regulations they outlined in their statement made in February 2020.
  • They confirmed that they are currently receiving high quality dossiers from CBD companies wishing to keep their products on the UK market.

A “validated” Novel Foods application is the first step, and a prerequisite, to gaining an authorised Novel Foods application. The FSA do not expect companies to have a fully authorised Novel Foods application by 31 March 2021.

In the statement, the ACI welcomed the clarification from the FSA and stated that they continue to work with their members to ensure they understand everything they need to know to keep their CBD products on sale in the UK.

It is now clear that if you do not have a validated Novels Foods dossier by 31 March 2021 you will not be able to legally sell your products in the UK.” the statement continues.

Due to the amount of data required to create a credible dossier, and time taken to generate this data, The ACI experts are advising CBD companies to start this process now, if they have not already done so.

Source: Association for the Cannabinoid Industry